stockrow
Saturday 7 November 2026
Export DTIL’s income statement to Excel — free account
Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.
- Revenue
- +37,272.4%
- EPS
- +85.0%
- Free cash flow
- −0.52%
- Total debt
- +0.22%
Quarter to September 2026, against a year earlier
10.75
0.88
+8.92%
Follow DTIL
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 3 | 2 | 5 | 1 | 3 | 4 | 1 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.97 | 0.00 |
P/S ratio |
25.26 | 25.26 | 25.26 | 26.20 | 17.85 | 3.76 | 4.10 | 0.88 | 0.38 | 1.56 |
Altman Z-Score |
— | — | — | 2.28 | (1.96) | 0.71 | (2.22) | (4.06) | (4.18) | (4.31) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.89 | 0.91 | 0.91 | 1.20 | (7.94) | (1.44) | (3.42) | (8.14) | (8.23) | (7.20) |
P/Operating CF |
(21.29) | (21.29) | (21.29) | (28.35) | (32.23) | (18.32) | (4.71) | (5.06) | (1.39) | (4.74) |
Beneish M-Score |
— | — | 11.91 | (2.26) | 6.62 | 0.12 | 0.63 | (0.68) | 0.14 | — |
P/B ratio |
6.88 | 6.88 | 6.88 | 4.21 | 9.76 | 4.76 | 1.70 | 2.26 | 0.46 | 0.58 |
Price to Tangible BV |
7.14 | 7.14 | 7.14 | 4.26 | 10.07 | 4.87 | 1.72 | 2.31 | 0.47 | 0.59 |
EV/Sales |
15.77 | 15.77 | 15.77 | 18.07 | 14.51 | 2.53 | (2.57) | (1.45) | (0.55) | (1.16) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20 | 1.97 | 1.70 | 0.80 |
EV/Operating CF |
(3.32) | (3.32) | (3.32) | (5.66) | (4.03) | (26.97) | 1.41 | 0.84 | 0.65 | 0.60 |
EV/FCF |
(2.60) | (2.60) | (2.60) | (4.20) | (3.81) | (18.40) | 1.31 | 0.82 | 0.65 | 0.60 |
Quick Ratio |
11.25 | 6.83 | 7.37 | 6.75 | 2.33 | 4.01 | 3.19 | 2.35 | 5.78 | 12.97 |
Current Ratio |
11.32 | 6.99 | 8.22 | 7.19 | 2.46 | 4.50 | 3.34 | 2.73 | 6.34 | 13.32 |
Net Debt/EBITDA |
11.41 | 3.08 | 2.27 | 2.21 | 0.81 | 4.84 | 3.12 | 3.24 | 2.87 | 1.86 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 5.72% | 1.17% | 9.33% | 0.00% | 16.37% | 14.51% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.03 | 0.37 | 0.00 | 0.40 | 0.24 |
Asset Turnover |
0.08 | 0.08 | 0.10 | 0.12 | 0.13 | 0.64 | 0.11 | 0.24 | 0.46 | 0.24 |
Operating CF/Net income |
(11.18) | 1.15 | 1.12 | 0.76 | 0.80 | 0.35 | 0.41 | 1.37 | (8.15) | 1.44 |
Capex/Depreciation |
0.00 | (3.55) | (6.06) | (4.64) | (0.51) | (0.57) | (0.38) | (0.28) | (0.06) | (0.31) |
Interest Coverage |
(30.98) | (25.20) | (25.55) | (479.14) | (133.61) | (298.30) | (56.08) | (19.61) | (14.68) | (36.67) |
| 53.02% | 135.60% | (677.86%) | (104.20%) | (119.30%) | (45.14%) | (147.28%) | (154.66%) | 19.05% | (61.52%) | |
| (9.64%) | (24.67%) | (43.58%) | (49.69%) | (56.57%) | (16.92%) | (49.65%) | (30.82%) | 4.84% | (31.45%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(9.21%) | (33.35%) | (37.51%) | (45.02%) | (111.43%) | (20.28%) | (73.81%) | (66.14%) | 8.62% | (41.10%) |
Average Days of Receivables |
20.08 | 1.24 | 17.54 | 15.84 | 150.30 | 1.54 | 10.47 | 6.75 | 1.22 | 0.00 |
Research and Development Expense of Revenue |
129.75% | 313.45% | 414.61% | 370.61% | 403.79% | 99.75% | 183.77% | 109.54% | 86.70% | 158.10% |
Selling, General and Administrative Expense of Revenue |
86.97% | 123.63% | 125.64% | 121.53% | 148.45% | 34.34% | 164.49% | 80.22% | 51.38% | 94.09% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 6.46% | 22.54% | 40.20% | 56.77% | 14.29% | 76.49% | 28.81% | 18.35% | 29.73% |
Graham Net Nets |
0.06 | 0.06 | 0.06 | 0.17 | 0.00 | 0.10 | 0.21 | (0.11) | 0.58 | 1.06 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.93 | 0.00 |
Earnings Yield |
(16.75%) | (16.75%) | (16.75%) | (22.70%) | (25.08%) | (7.03%) | (119.78%) | (144.79%) | 50.66% | (123.08%) |
Free Cash Flow Yield |
(24.01%) | (24.01%) | (24.01%) | (16.42%) | (21.32%) | (3.67%) | (47.72%) | (202.38%) | (225.60%) | (124.59%) |
Revenue per Share |
0.14 | 12.24 | 20.72 | 15.90 | 14.02 | 59.12 | 8.57 | 12.69 | 10.05 | 2.67 |
Operating CF per Share |
1.84 | (45.63) | (98.46) | (50.79) | (50.43) | (5.55) | (15.62) | (21.90) | (8.55) | (5.13) |
Capex per Share |
0.00 | (10.41) | (27.15) | (17.64) | (2.90) | (2.97) | (1.13) | (0.57) | (0.03) | (0.05) |
Free Cash Flow per Share |
1.84 | (56.04) | (125.62) | (68.43) | (53.34) | (8.52) | (16.75) | (22.46) | (8.58) | (5.18) |
Cash per Share |
1.86 | 118.56 | 196.45 | 129.36 | 51.83 | 73.51 | 64.70 | 30.38 | 12.63 | 9.01 |
Shareholders Equity per Share |
(0.09) | (49.78) | 76.07 | 98.92 | 25.64 | 46.65 | 20.63 | 4.91 | 8.25 | 7.19 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.09) | (49.78) | 76.07 | 98.92 | 25.64 | 46.65 | 20.63 | 4.91 | 8.25 | 7.19 |
Free Cash Flow |
92.27 | (29.68) | (65.99) | (95.68) | (92.42) | (16.66) | (49.07) | (86.28) | (58.66) | (66.48) |
Working Capital |
86.06 | 55.13 | 101.60 | 166.74 | 62.74 | 125.77 | 139.44 | 86.37 | 80.01 | 109.83 |
Capital Expenditures |
(2.07) | (5.51) | (14.26) | (24.67) | (5.03) | (5.80) | (3.32) | (2.17) | (0.21) | (0.63) |
Net Current Asset Value |
(8.76) | (34.72) | 17.04 | 96.75 | (0.17) | 41.42 | 21.37 | (4.56) | 14.99 | 56.57 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.04 | 1.62 | 1.45 | 0.76 |
Capex to Sales |
0.00 | 0.85 | 1.31 | 1.11 | 0.21 | 0.05 | 0.13 | 0.04 | 0.00 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.18 | 0.19 | 0.11 | 0.13 | 0.28 | 0.40 | 0.73 | 1.22 | 1.26 | 1.45 |
Cash ROIC |
104.06% | (81.48%) | (46.09%) | (29.98%) | (64.71%) | (7.02%) | (18.03%) | (63.66%) | (35.55%) | (28.87%) |
Accounts Receivable Turnover |
34.39 | 31.78 | 39.94 | 29.89 | 4.43 | 22.03 | 41.55 | 60.12 | 121.59 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
0.20 | 0.20 | 0.27 | 0.74 | 5.48 | 5.24 | 0.60 | 0.81 | 0.57 | — |
Average Payables |
1.55 | 1.55 | 2.01 | 2.13 | 1.41 | 0.97 | 0.90 | 1.81 | 2.14 | 0.80 |
Average Assets |
85.55 | 85.55 | 105.64 | 186.92 | 192.70 | 180.83 | 224.83 | 198.98 | 148.08 | 145.40 |
Average Common Equity |
(15.56) | (15.56) | 6.79 | 89.13 | 91.37 | 67.80 | 75.80 | 39.65 | 37.63 | 74.32 |
Columns are period end dates · fundamentals updated 5 Nov 2026